Healthcare / Drug Manufacturers - GeneralKSE
$3080.00
-80.00 (-2.53%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $2.1B · quality 44.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$67.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-79.7%
↓Gross Margin
64.5%
↑Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.7%
FCF CAGR
—
FCF margin
1.5%
FCF / Net income
-0.02x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $173.07B · net income $-116.64B · FCF $2.65B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $173.07B | $173.07B | $171.29B | $166.78B | $150.93B |
| Net Income | $-116.64B | $-116.64B | $2.79B | $6.09B | $70.06B |
| EBITDA | $-145.15B | $-145.15B | $9.81B | $16.96B | $96.84B |
| EPS | — | — | 152.00 | 324.00 | 3369.00 |
| Gross Margin | 64.5% | 64.5% | 63.1% | 58.7% | 53.9% |
| Operating Margin | 3.5% | 3.5% | 6.2% | 5.5% | 5.0% |
| Net Margin | -67.4% | -67.4% | 1.6% | 3.7% | 46.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.16 | 0.16 | 0.19 |
| Current Ratio | 2.08 | 2.08 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $2.65B | $2.65B | $-399.3M | $2.15B | $-13.24B |
| Returns | |||||
| ROE | -79.7% | -79.7% | 1.1% | 2.6% | 33.8% |
| Valuation | |||||
| P/E | — | — | 28.59 | 19.41 | 2.03 |
| EV/EBITDA | — | — | 9.76 | 7.03 | 1.68 |
| P/B | 0.46 | 0.46 | 0.38 | 0.51 | 0.69 |
| Growth & Yield | |||||
| Revenue Growth | 1.0% | 1.0% | 2.7% | 10.5% | — |
| EPS Growth | — | — | -53.1% | -90.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.0%
Start / end P/E
n/dx → n/dx
EPS bridge
152.00 → n/d
Residual
-23.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.